Efficacy of Revisional Endoscopic Sleeve Gastroplasty After Laparoscopic Sleeve Gastrectomy.

IF 2.9 3区医学 Q1 SURGERY

Obesity Surgery Pub Date : 2025-02-01 Epub Date: 2025-01-08 DOI:10.1007/s11695-024-07665-9

John Deng, Julia Wool, Ronald Blanco Montecino, Alvaro Cadillo Arbaiza, Luyu Xie, Sarah E Messiah, Sunil Matthew, Shannon Shiffer, Jaime P Almandoz, Anna Tavakkoli

{"title":"Efficacy of Revisional Endoscopic Sleeve Gastroplasty After Laparoscopic Sleeve Gastrectomy.","authors":"John Deng, Julia Wool, Ronald Blanco Montecino, Alvaro Cadillo Arbaiza, Luyu Xie, Sarah E Messiah, Sunil Matthew, Shannon Shiffer, Jaime P Almandoz, Anna Tavakkoli","doi":"10.1007/s11695-024-07665-9","DOIUrl":null,"url":null,"abstract":"Background: Recurrent weight gain after laparoscopic sleeve gastrectomy (LSG) is common. Revisional endoscopic sleeve gastroplasty (r-ESG) has been shown to be a promising endoscopic bariatric therapy (EBT) to treat weight recurrence after LSG. However, to date, weight loss outcomes beyond 1-year follow-up are unknown. Our study aims as follows: (1) examine 1 year, 18-month, and 24-month weight loss outcomes post-r-ESG and (2) determine if weight loss outcomes post-LSG predict clinical outcomes post-r-ESG.Methods: This was a retrospective cohort data of patients who completed r-ESG from December 2020 to November 2023. The primary outcome was percentage of total body weight loss (TBWL) at 1-year post-r-ESG. Secondary outcomes included TBWL at 18- and 24-month post-r-ESG. Multivariable logistic regression analysis was used to determine predictors of weight loss ≥ 5% at 12 months.Results: A total of 55 patients completed r-ESG. TBWL post-r-ESG at 12 months was 8.6% (n = 37), at 18 months was 10.7% (n = 31), and at 24 months was 12.6% (n = 18) (Table 2). There were no statistically significant variables associated with weight loss ≥ 5% at 12 months (Table 3).Conclusions: Our study demonstrates that r-ESG is an effective and durable EBT for post-LSG weight recurrence. Further research is needed to determine optimal timing of r-ESG for weight recurrence as well as the adjunctive role of anti-obesity medications.","PeriodicalId":19460,"journal":{"name":"Obesity Surgery","volume":" ","pages":"582-586"},"PeriodicalIF":2.9000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obesity Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11695-024-07665-9","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/8 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Recurrent weight gain after laparoscopic sleeve gastrectomy (LSG) is common. Revisional endoscopic sleeve gastroplasty (r-ESG) has been shown to be a promising endoscopic bariatric therapy (EBT) to treat weight recurrence after LSG. However, to date, weight loss outcomes beyond 1-year follow-up are unknown. Our study aims as follows: (1) examine 1 year, 18-month, and 24-month weight loss outcomes post-r-ESG and (2) determine if weight loss outcomes post-LSG predict clinical outcomes post-r-ESG.

Methods: This was a retrospective cohort data of patients who completed r-ESG from December 2020 to November 2023. The primary outcome was percentage of total body weight loss (TBWL) at 1-year post-r-ESG. Secondary outcomes included TBWL at 18- and 24-month post-r-ESG. Multivariable logistic regression analysis was used to determine predictors of weight loss ≥ 5% at 12 months.

Results: A total of 55 patients completed r-ESG. TBWL post-r-ESG at 12 months was 8.6% (n = 37), at 18 months was 10.7% (n = 31), and at 24 months was 12.6% (n = 18) (Table 2). There were no statistically significant variables associated with weight loss ≥ 5% at 12 months (Table 3).

Conclusions: Our study demonstrates that r-ESG is an effective and durable EBT for post-LSG weight recurrence. Further research is needed to determine optimal timing of r-ESG for weight recurrence as well as the adjunctive role of anti-obesity medications.

查看原文本刊更多论文

腹腔镜袖胃切除术后内镜改良袖胃成形术的疗效。

背景：腹腔镜袖胃切除术（LSG）后复发性体重增加是常见的。内镜下修正胃套筒成形术（r-ESG）已被证明是一种很有前途的内镜下减肥疗法（EBT），用于治疗LSG后体重复发。然而，到目前为止，超过1年的随访减肥结果尚不清楚。我们的研究目的如下：(1)检查r- esg后1年、18个月和24个月的体重减轻结果；(2)确定lsg后的体重减轻结果是否能预测r- esg后的临床结果。方法：这是2020年12月至2023年11月完成r-ESG的患者的回顾性队列数据。主要终点是r- esg后1年的总体重减轻百分比（TBWL）。次要结局包括r- esg后18个月和24个月的TBWL。采用多变量logistic回归分析确定12个月体重减轻≥5%的预测因素。结果：55例患者完成r-ESG。r-ESG术后12个月的TBWL为8.6% (n = 37)， 18个月为10.7% (n = 31)， 24个月为12.6% (n = 18)（表2）。12个月时体重减轻≥5%的相关变量无统计学意义（表3）。结论：我们的研究表明r-ESG是一种有效且持久的治疗lsg术后体重复发的EBT。需要进一步的研究来确定体重复发的r-ESG的最佳时机以及抗肥胖药物的辅助作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Obesity Surgery 医学-外科

CiteScore

5.80

自引率

24.10%

发文量

567

审稿时长

3-6 weeks

期刊介绍： Obesity Surgery is the official journal of the International Federation for the Surgery of Obesity and metabolic disorders (IFSO). A journal for bariatric/metabolic surgeons, Obesity Surgery provides an international, interdisciplinary forum for communicating the latest research, surgical and laparoscopic techniques, for treatment of massive obesity and metabolic disorders. Topics covered include original research, clinical reports, current status, guidelines, historical notes, invited commentaries, letters to the editor, medicolegal issues, meeting abstracts, modern surgery/technical innovations, new concepts, reviews, scholarly presentations and opinions. Obesity Surgery benefits surgeons performing obesity/metabolic surgery, general surgeons and surgical residents, endoscopists, anesthetists, support staff, nurses, dietitians, psychiatrists, psychologists, plastic surgeons, internists including endocrinologists and diabetologists, nutritional scientists, and those dealing with eating disorders.